CDKN2A Gene clinical trials
18 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
- Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
- Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- Palbociclib and Pembrolizumab In Central Nervous System Metastases
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
- Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
- Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- The Cancer of the Pancreas Screening-5 CAPS5)Study
- A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
- Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
- Pancreatic Cancer Screening for At-risk Individuals
- A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
- Pancreatic Cancer Early Detection Consortium
- Pancreas Registry and High Risk Registry
- Prospective Familial Registry for Pancreas Research
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “CDKN2A Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.